Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 3/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25035645 | 0.98 | ERN1 (0.47) | ERN1BRAFMTORJAK1CYP1A2 | |
| SCHEMBL25035646 | 0.96 | ERN1 (0.49) | ERN1BRAFMTORJAK1CYP1A2 | |
| SCHEMBL25035563 | 0.90 | ERN1 (0.49) | ERN1BRAFMTORJAK1CYP1A2 | |
| SCHEMBL25035404 | 0.89 | ERN1 (0.49) | ERN1BRAFMTORCYP1A2CYP3A4 | |
| SCHEMBL25035694 | 0.88 | ERN1 (0.51) | ERN1BRAFMTORJAK1CYP1A2 | |
| SCHEMBL25035637 | 0.88 | ERN1 (0.51) | ERN1BRAFMTORJAK1CYP1A2 | |
| SCHEMBL25034134 | 0.87 | ERN1 (0.50) | ERN1BRAFMTORJAK1CYP1A2 | |
| SCHEMBL25035522 | 0.87 | ERN1 (0.53) | ERN1BRAFMTORCYP1A2CYP3A4 | |
| SCHEMBL25035642 | 0.87 | ERN1 (0.50) | ERN1BRAFMTORJAK1CYP1A2 | |
| SCHEMBL25035556 | 0.87 | ERN1 (0.47) | ERN1BRAFMTORCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | ERN1 3167/4885BRAF 563/4885MTOR 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.